Status:

COMPLETED

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Conditions:

Crohn's Disease

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance tr...

Detailed Description

Study C13007 comprised 2 randomized, double-blind, placebo-controlled studies conducted under 1 protocol which, operationally, consisted of 2 phases. * The Induction Phase, designed to establish the ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age 18 to 80
  • Diagnosis of moderately to severely active Crohn's disease (CD)
  • CD involvement of the ileum and/or colon
  • Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:
  • Immunomodulators
  • Tumor necrosis factor-alpha (TNFα) antagonists
  • Corticosteroids
  • May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol
  • Exclusion Criteria
  • Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine
  • Extensive colonic resection, subtotal or total colectomy
  • History of \>3 small bowel resections or diagnosis of short bowel syndrome
  • Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  • Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
  • Chronic hepatitis B or C infection
  • Active or latent tuberculosis

Exclusion

    Key Trial Info

    Start Date :

    December 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2012

    Estimated Enrollment :

    1116 Patients enrolled

    Trial Details

    Trial ID

    NCT00783692

    Start Date

    December 1 2008

    End Date

    May 1 2012

    Last Update

    July 21 2014

    Active Locations (114)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 29 (114 locations)

    1

    University of Alabama at Birmingham

    Birmingham, Alabama, United States, 35233

    2

    Apex Clinical Trials

    Birmingham, Alabama, United States, 35234

    3

    Gastrointestinal Bioscience

    Los Angeles, California, United States, 90067

    4

    Paramount Medical Specialty

    Montebello, California, United States, 90640